Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing because — yes, you guessed it — that familiar routine of meetings, deadlines, endless texting, and conference calls has resumed. But what can you do? The world keeps spinning, no matter how much we push back. So join us as we surrender to the frantic pace with a cup or three of stimulation. Our choice today is hot-buttered rum — yum. Meanwhile, here are some tidbits. Have a splendid day and do keep in touch …

Democratic lawmakers in recent weeks have begun to advance an argument long seen as something of a third rail in U.S. politics: that slightly less biomedical innovation might be worth a dramatic reduction in drug prices, STAT explains. The surprising candor has come amid pushback to House Speaker Nancy Pelosi’s high-profile drug pricing bill, which the trade group PhRMA this month said represented “nuclear winter” for the development of new medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!